ICOSLG介导的调节性T细胞扩增与IL-10产生促进胶质母细胞瘤进展
该研究探讨ICOSLG在胶质母细胞瘤(GBM)进展中的因果作用,分析人脑胶质瘤组织及患者来源的GBM球细胞(GSC)。生物信息学和组织芯片显示ICOSLG上调与GBM患者不良预后相关,且在间充质型GSC中以TNF-α/NF-κB依赖方式优先上调。间充质型GSC表达的ICOSLG促进产生IL-10的T细胞扩增,敲低ICOSLG基因在免疫健全小鼠中显著减少GBM肿瘤生长并下调肿瘤微环境IL-10水平。
要点
- ICOSLG高表达与GBM患者不良预后相关
- ICOSLG在间充质型GSC中经TNF-α/NF-κB通路上调
- 敲低ICOSLG可减少免疫健全小鼠GBM生长并降低IL-10
核心结论
- 抑制ICOSLG-ICOS轴可能为间充质特征升高的GBM亚群提供有前景的免疫治疗途径。
研究设计与样本
- 研究分析人脑胶质瘤组织与患者来源GBM球细胞(GSC)中ICOSLG表达,并检测其免疫调节效应及分子机制。
- 在免疫健全小鼠中敲低ICOSLG基因并观察GBM肿瘤生长与肿瘤微环境IL-10水平。
主要发现
- 生物信息学分析及GBM组织芯片显示ICOSLG表达上调与GBM患者不良预后相关。
- ICOSLG在间充质型GSC而非前神经型GSC中以TNF-α/NF-κB依赖方式优先上调。
- 间充质型GSC表达的ICOSLG促进产生IL-10的T细胞扩增。
- 敲低ICOSLG基因在免疫健全小鼠中显著减少GBM肿瘤生长,并伴随肿瘤微环境IL-10水平下调。
临床怎么用
- ICOSLG高表达可作为GBM(尤其间充质型)预后不良的参考标志。
- 靶向ICOSLG-ICOS轴可能成为间充质特征升高GBM亚群的免疫治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeting immune checkpoint proteins has recently gained substantial attention due to the dramatic success of this strategy in clinical trials for some cancers. Inducible T-cell co-stimulator ligand (ICOSLG) is a member of the B7 family of immune regulatory ligands, expression of which in cancer is implicated in disease progression due to regulation of antitumor adaptive immunity. Although aberrant ICOSLG expression has been reported in glioma cells, the underlying mechanisms that promote glioblastoma (GBM) progression remain elusive. METHODS: Here, we investigated a causal role for ICOSLG in GBM progression by analyzing ICOSLG expression in both human glioma tissues and patient-derived GBM sphere cells (GSCs). We further examined its immune modulatory effects and the underlying molecular mechanisms. RESULTS: Bioinformatics analysis and GBM tissue microarray showed that upregulation of ICOSLG expression was associated with poor prognosis in patients with GBM. ICOSLG expression was upregulated preferentially in mesenchymal GSCs but not in proneural GSCs in a tumor necrosis factor-α/nuclear factor-kappaB-dependent manner. Furthermore, ICOSLG expression by mesenchymal GSCs promoted expansion of T cells that produced interleukin-10. Knockdown of the gene encoding ICOSLG markedly reduced GBM tumor growth in immune competent mice, with a concomitant downregulation of interleukin-10 levels in the tumor microenvironment. CONCLUSIONS: Inhibition of the ICOSLG-inducible co-stimulator axis in GBM may provide a promising immunotherapeutic approach for suppressing a subset of GBM with an elevated mesenchymal signature.
引用
- Iwata R, Hyoung Lee J, Hayashi M, et al. ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma. Neuro Oncol. 2020. PMID: 31634400. doi:10.1093/neuonc/noz204
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。